ROSIGLITAZONE-BASED THERAPY REDUCES INFLAMMATORY BIOMARKERS IN DIABETIC, HYPERTENSIVE PATIENTS COMPARED TO A METFORMIN AND GLYBURIDE BASED-REGIMEN: THE ROSITEL RANDOMIZED TRIAL Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Gupta, M
  • Teoh, H
  • Kajil, M
  • Tsigoulis, M
  • Quan, A
  • Braga, Manoela
  • Verma, S

publication date

  • October 1, 2010